The NEOLETRIB trial: Neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer Journal Article
| Authors: | Fjermeros, K.; Ghannoum, S.; Geisler, S. B.; Bhargava, S.; Tahiri, A.; Klajic, J.; Lüders, T.; Fongård, M.; Nawaz, M. S.; Bosnjak-Olsen, T.; Buvarp, U. C. E.; Rosenskiold, A. K. J.; Nguyen, N. T.; Sletbak, T. T.; Seyedzadeh, M.; Selsås, K.; Porojnicu, A. C.; Skjerven, H. K.; Hovda, T.; Sahlberg, K. K.; Torland, L. A.; Lyngra, M.; Hammarström, C. L.; Hönigsperger, E. B.; Noone, J. C.; Mathiassen, S.; Hurtado, A.; Goel, S.; Koff, A.; Tekpli, X.; Kristensen, V. N.; Geisler, J. |
| Article Title: | The NEOLETRIB trial: Neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer |
| Abstract: | Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be an appropriate alternative in selected patients. Thus, the NEOLETRIB trial evaluates the response of ER-positive, HER2-negative luminal A/B breast cancer to the combination of letrozole and ribociclib in the neoadjuvant setting. Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment. Trial registration number:NCT05163106 (ClinicalTrials.gov). © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; cancer chemotherapy; treatment outcome; middle aged; major clinical study; overall survival; cancer radiotherapy; neoadjuvant therapy; nuclear magnetic resonance imaging; antineoplastic agent; cell proliferation; tumor associated leukocyte; phenotype; metabolism; apoptosis; computer assisted tomography; multiple cycle treatment; gene expression; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; tumor biopsy; pathology; breast neoplasms; cancer therapy; histology; goserelin; radiologist; breast tumor; tumor immunity; purines; receptor, erbb-2; receptors, estrogen; purine derivative; letrozole; senescence; neoadjuvant chemotherapy; molecular biology; estrogen receptor; drug therapy; intestine flora; cytokine release; postmenopause; electrocardiogram; neoadjuvant; follitropin; tumor microenvironment; erbb2 protein, human; exosome; procedures; humans; human; female; article; whole genome sequencing; gut microbiome; aminopyridines; locally advanced breast cancer; ribociclib; aminopyridine derivative; whole exome sequencing; single-cell rna sequencing; single cell rna seq; estrogen receptor-positive, her2-negative breast cancer; hr positive |
| Journal Title: | Future Oncology |
| Volume: | 20 |
| Issue: | 32 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2024-01-01 |
| Start Page: | 2457 |
| End Page: | 2466 |
| Language: | English |
| DOI: | 10.1080/14796694.2024.2377531 |
| PUBMED: | 39073142 |
| PROVIDER: | scopus |
| PMCID: | PMC11520546 |
| DOI/URL: | |
| Notes: | Source: Scopus |
